CAMBRIDGE, England, November 25 /PRNewswire/ -- Cambridge Bioscience Partnership Ltd today announced that it has entered into an agreement with NeurAxon. Under the terms of the agreement Cambridge Bioscience Partnership Ltd will provide assay development and screening services to NeurAxon for research on undisclosed targets.
Drs Bob Gordon and Ed Zanders, co-founders and Directors of Cambridge Bioscience Partnership Ltd, said: "We are delighted to be working with NeurAxon Inc. This agreement is precisely in line with our strategy of partnering our assay development and screening capabilities."
Dr John Andrews, President of NeurAxon Inc commented: "It is a pleasure to be collaborating with a company like Cambridge Bioscience Partnership Ltd that can be trusted to deliver a highly professional service."
Cambridge Bioscience Partnership Ltd
Based in Cambridge UK, the company draws on the expertise of a highly experienced team of industrial scientists to provide drug discovery consultancy and laboratory services. Current customers include Cytomyx Ltd and Purely Proteins Ltd.
NeurAxon Inc. is developing new drugs for the treatment of pain and other CNS disorders. NeurAxon Inc. believes good science can make a difference in improving the quality of life for people suffering from chronic pain.
Cambridge BioScience Partnership Ltd
CONTACT: Contact Details: Cambridge Bioscience Partnership Ltd, StJohn's Innovation Centre, Cowley Road, Cambridge CB4 0WS,United Kingdom, Tel: +44-(0)1223-208534, Fax:+44-(0)1223-207378, Email: firstname.lastname@example.org; NeurAxon Inc,16-1375 Southdown Road, Suite 318, Mississauga, Ontario, CanadaL5J 2Z1; Tel: +1-905-823-3110, Email: email@example.com